ReviewInternational journal of molecular sciences2026
Molecular Biomarkers Linking Psoriasis and Cardiovascular Disease: Current Evidence and Clinical Perspectives.
Review in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Psoriasis is a chronic, immune-mediated inflammatory disease affecting the skin, nails, and joints. Its complex pathogenesis results from interactions between genetic susceptibility and environmental factors and is accompanied by an increased risk of multiple systemic comorbidities, particularly cardiovascular disease. Growing evidence indicates that both conditions share common molecular pathways driven by chronic inflammation, endothelial dysfunction, metabolic disturbances, and immune dysregulation. Among the emerging molecular biomarkers, chemerin, endocan, and growth differentiation factor-15 (GDF-15) have attracted considerable attention due to their role in vascular homeostasis, adipose tissue biology, glucose metabolism, and inflammatory signaling. This review summarizes current evidence on the involvement of these biomarkers in psoriasis and cardiovascular disease, highlighting their contribution to the molecular mechanisms underlying the psoriasis-cardiovascular disease axis. Furthermore, we discussed their potential usefulness as candidate biomarkers for cardiovascular risk. However, prospective validation is strictly required to confirm their clinical utility and establish their incremental predictive value beyond conventional risk factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.